Samil Pharmaceutical Co.,Ltd (KRX:000520)
South Korea
· Delayed Price · Currency is KRW 9,100.00
-290.00 (-3.09%)
Apr 29, 2026, 3:30 PM KST
KRX:000520 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 210,253 | 219,700 | 196,346 | 179,676 | 134,247 | Upgrade
|
| Other Revenue | -0 | -0 | - | -0 | - | Upgrade
|
| Revenue | 210,253 | 219,700 | 196,346 | 179,676 | 134,247 | Upgrade
|
| Revenue Growth (YoY) | -4.30% | 11.89% | 9.28% | 33.84% | 9.14% | Upgrade
|
| Cost of Revenue | 133,135 | 138,785 | 122,275 | 112,191 | 85,259 | Upgrade
|
| Gross Profit | 77,118 | 80,914 | 74,071 | 67,486 | 48,988 | Upgrade
|
| Selling, General & Admin | 79,820 | 68,747 | 61,138 | 57,746 | 43,287 | Upgrade
|
| Research & Development | 8,463 | 6,513 | 5,601 | 2,907 | 2,971 | Upgrade
|
| Amortization of Goodwill & Intangibles | 824.2 | 259.25 | 265.05 | 199.72 | 236.07 | Upgrade
|
| Other Operating Expenses | 729.71 | 651.37 | 516.12 | 637.98 | 623.15 | Upgrade
|
| Operating Expenses | 101,057 | 80,866 | 67,611 | 63,469 | 48,589 | Upgrade
|
| Operating Income | -23,938 | 48.11 | 6,460 | 4,017 | 399.74 | Upgrade
|
| Interest Expense | -8,772 | -5,057 | -3,545 | -4,263 | -6,202 | Upgrade
|
| Interest & Investment Income | 51.17 | 62.84 | 34.72 | 70.02 | 129.99 | Upgrade
|
| Earnings From Equity Investments | 0.53 | 0.42 | 0.49 | 122.8 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -226.35 | -357.06 | -277.57 | 197.76 | 246.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,091 | 1,718 | -2,367 | 580.12 | 299.46 | Upgrade
|
| EBT Excluding Unusual Items | -33,976 | -3,586 | 306.5 | 724.39 | -5,127 | Upgrade
|
| Gain (Loss) on Sale of Investments | -229.35 | - | -585 | -7.11 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.14 | -27.07 | 1,702 | 340.82 | 365.84 | Upgrade
|
| Other Unusual Items | -2,954 | - | - | - | - | Upgrade
|
| Pretax Income | -37,158 | -3,613 | 1,424 | 1,058 | -4,761 | Upgrade
|
| Income Tax Expense | -2,495 | 2,016 | -239.76 | 1,086 | 585.31 | Upgrade
|
| Net Income | -34,664 | -5,629 | 1,664 | -28.29 | -5,347 | Upgrade
|
| Net Income to Common | -34,664 | -5,629 | 1,664 | -28.29 | -5,347 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 18 | 14 | 14 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 18 | 14 | 14 | 14 | Upgrade
|
| Shares Change (YoY) | 18.05% | 24.32% | 3.75% | 0.82% | 2.85% | Upgrade
|
| EPS (Basic) | -1632.80 | -313.00 | 116.16 | -2.03 | -386.63 | Upgrade
|
| EPS (Diluted) | -1633.00 | -313.00 | 115.00 | -2.03 | -386.63 | Upgrade
|
| Free Cash Flow | -6,888 | -2,782 | -12,498 | -44,327 | -31,411 | Upgrade
|
| Free Cash Flow Per Share | -324.47 | -154.68 | -864.01 | -3179.28 | -2271.39 | Upgrade
|
| Gross Margin | 36.68% | 36.83% | 37.72% | 37.56% | 36.49% | Upgrade
|
| Operating Margin | -11.39% | 0.02% | 3.29% | 2.23% | 0.30% | Upgrade
|
| Profit Margin | -16.49% | -2.56% | 0.85% | -0.02% | -3.98% | Upgrade
|
| Free Cash Flow Margin | -3.28% | -1.27% | -6.37% | -24.67% | -23.40% | Upgrade
|
| EBITDA | -14,741 | 7,311 | 11,828 | 9,006 | 5,112 | Upgrade
|
| EBITDA Margin | -7.01% | 3.33% | 6.02% | 5.01% | 3.81% | Upgrade
|
| D&A For EBITDA | 9,197 | 7,263 | 5,368 | 4,989 | 4,712 | Upgrade
|
| EBIT | -23,938 | 48.11 | 6,460 | 4,017 | 399.74 | Upgrade
|
| EBIT Margin | -11.39% | 0.02% | 3.29% | 2.23% | 0.30% | Upgrade
|
| Effective Tax Rate | - | - | - | 102.67% | - | Upgrade
|
| Advertising Expenses | 8,259 | 8,069 | 8,699 | 11,389 | 7,674 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.